Latest Distribution Agreements News

SportsHero Limited has entered the Southeast Asian mobile gaming market by signing an exclusive distribution agreement with Yes2Games, bringing globally popular titles like Fruit Ninja and Jetpack Joyride to Indonesia, the Philippines, Thailand, and Malaysia.

Anteris Technologies Global Corp. reported a $42.7 million net loss for the first half of 2025 amid advancing preparations for its pivotal DurAVR Transcatheter Heart Valve trial. The company’s recent IPO proceeds are fueling R&D and manufacturing scale-up as it targets regulatory approvals.

Atomo Diagnostics has secured a US$410,000 order from Lumos Diagnostics for its Pascal test cassettes, following Lumos's exclusive six-year US distribution deal for the FebriDx test with PHASE Scientific.

AMP reported a 9.2% increase in underlying net profit after tax to $131 million for the first half of 2025, driven by robust cashflow growth and steady performances across its wealth and banking divisions. The company also declared a 2.0 cents per share interim dividend, maintaining disciplined cost control amid ongoing strategic investments.

RooLife Group (ASX, RLG) reported $1 million revenue in Q4 FY2025, driven by its UK TikTok marketplace launch and a major solar product order from India, while divesting its digital marketing arm and cutting staff costs.

Aumake Limited reported a remarkable 213% surge in quarterly cash receipts, driven by exclusive distribution agreements and strategic cost reductions, setting the stage for profitability in FY26.

SportsHero Limited has advanced its iGV Family Game Pass commercialization with launches in Indonesia and the Philippines, backed by new Telco partnerships and a A$1.65 million capital raise.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.

ClearVue Technologies has announced a major leadership overhaul alongside strategic partnerships and market expansion, highlighted by a solar façade trial in Hong Kong demonstrating a payback period as low as 2.6 years.

Starpharma reports a 165% rise in FY25 customer receipts, advances its clinical-stage DEP® assets, and secures new distribution deals in Asia and Saudi Arabia.

Associate Global Partners Limited reported an 11% increase in funds under management to $1.397 billion for the June quarter 2025, alongside sustained positive operating cash flows and strong fund performance from its WCM strategies.

Acrux Limited has secured a decade-long licensing agreement with Servacure to commercialise its FDA-approved Dapsone 5% Gel in Saudi Arabia, marking a strategic step in its global expansion.